August 16, 2017October 16, 2017 by Ian Johnson

SWOG S1418

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

What We’ve Been Up to Lately

Our research team was recently awarded with the Gold Certificate of Excellence by the NCI Community Oncology Research Program. This award is given to research teams who are able to enroll a specified number of patients onto NCI sponsored clinical trials within a certain time period. Our team is one of 43 total to have been given this award so far this year. We would not have been able to earn this award without the help of our wonderful patients and is a testament to them!